ClinicalTrials.gg
RecruitingNCT06976918RHODOLITEUpdated Jun 5, 2026

Research Platform Myelofibrosis and Anemia

An observational study in Primary Myelofibrosis, Secondary Myelofibrosis and Post-polycythemia Vera Myelofibrosis, sponsored by iOMEDICO AG. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by iOMEDICO AG · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Primary Myelofibrosis with a site in Germany — 15 open to participants now, 29 under way, 9 of them phase 3. Primary Myelofibrosis · Germany.

Started
2026
with 3 others
Observational
5 of 75
2 open now
Primary completion
2031-09
later than 27 of 28 live
Registered
71st of 75
by date

Among the 75 studies in Primary Myelofibrosis with a site in Germany, this one is one of 4 that started in 2026, is one of 5 observational ones, reaches primary completion later than 27 of the 28 other live ones, and was the 71st registered.

Primary Myelofibrosis

628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

15 of the 75 studies in Primary Myelofibrosis with a site in Germany are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Primary Myelofibrosis with a site in Germany, or all of them as a file.
02

Study summary

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor research platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease and to collect patient-reported outcomes for patients with primary and secondary myelofibrosis and anemia in Germany.

Read the detailed description

RHODOLITE is a national, prospective, open-label, longitudinal, non-interventional multicenter cohort study (research platform) to describe treatment in routine clinical practice of myelofibrosis patients in routine care in Germany.

RHODOLITE will follow patients for up to three years with the aim to identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments and outcome are documented.

Health-related quality of life (HRQoL) will be evaluated for up to three years.

The RHODOLITE project is a joint project with the German Study Group for Myeloproliferative Neoplasms (GSG-MPN) and its GSG-MPN Bioregistry (NCT03125707). Details on treatment and outcome will be collected in RHODOLITE for up to three years, while long-term follow-up for a minimum of additional five years will be performed in the GSG-MPN Bioregistry.

03

Conditions studied

  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis
  • Anemia
  • Myelofibrosis; Anemia
  • Myelofibrosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with primary myelofibrosis or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (MF) with anemia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) (Note: diagnosis according to WHO-2017, ICC-2022 or WHO-2022 or IWG-MRT criteria, respectively).
  • Diagnosis of anemia at the time of enrollment as per individual, clinical assessment by the local physician.
  • Start of first or subsequent systemic treatment for MF.
  • and registration for the GSG-MPN Bioregistry.
  • Willingness and capability to participate in PRO assessment.
  • Signed and dated informed consent form for RHODOLITE at the latest six weeks after start of the respective systemic MF treatment.

Exclusion criteria

Exclusion Criteria:

  • No systemic therapy for diagnosed primary or secondary MF.
  • Planned allogenic stem cell transplantation (allo-SCT) or active participation in an interventional clinical trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Documentation of systemic treatment for MF and therapy sequences

    Types and frequencies of systemic treatment for MF during observation time.

    Time frame: 3 years per patient

Secondary outcomes

  1. Hematologic response

    Frequencies of hematologic response (improved, stable, worsened) per line of treatment

    Time frame: 3 years per patient

  2. Splenic response

    Frequencies of splenic response (improved, stable, worsened) per line of treatment

    Time frame: 3 years per patient

  3. Overall response rate (ORR)

    Documentation of ORR per line of treatment

    Time frame: 3 years per patient

  4. Progression free survival (PFS)

    Documentation of PFS per line of treatment

    Time frame: 3 years per patient

  5. Overall survival

    Documentation of OS per line of treatment

    Time frame: 3 years per patient

  6. Health-related quality of life (Patient-reported outcome, PRO)

    European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (EORTC QLQ-C30, the lower the score the better the QoL)

    Time frame: 3 years per patient

  7. Assessment of Myelofibrosis-related symptoms

    Myelofibrosis Symptom Assessment form (MFSAF) questionnaire 7-day Recall

    Time frame: 3 years per patient

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Sep 2031, 67 months after the start.

Of 23 observational studies under Primary Myelofibrosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 119. This study's planned 67 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 16, 2025
StartActual
Feb 19, 2026
Primary completionEst.
Sep 2031
CompletionEst.
Sep 2031
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06976918
Lead sponsor
iOMEDICO AG
Collaborators
German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
Responsible party
Sponsor
First posted
May 16, 2025
Start date
Feb 19, 2026
Primary completion
Sep 2031 (estimated)
Completion
Sep 2031 (estimated)
Last update
Jun 5, 2026

Study contacts

iOMEDICO AG
Contact
info@iomedico.com
+4976115242 ext. 0
Konstanze Döhner, Prof. Dr. med.
study chair · University Hospital Ulm, Germany
Steffen Koschmieder, Prof. Dr. med.
study chair · University Hospital Aachen, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion